{"id":"f0434","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for F0434 are limited in public literature, Merck KGaA's phase 3 pipeline typically includes agents targeting immune checkpoints or enhancing anti-tumor immunity. The exact molecular target and mechanism require access to clinical trial protocols or company disclosures.","oneSentence":"F0434 is an investigational immunotherapy agent designed to modulate immune responses, likely through checkpoint inhibition or T-cell activation pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:12:10.614Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT01263132","phase":"PHASE3","title":"Neuropathic Pain Management","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-02","conditions":"Diabetic Neuropathies, Polyneuropathies","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gabapentin with thiamine and cobalamin"],"phase":"phase_3","status":"active","brandName":"F0434","genericName":"F0434","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}